key: cord-1054920-x6hc4bhn
authors: Drayman, Nir; Jones, Krysten A.; Azizi, Saara-Anne; Froggatt, Heather M.; Tan, Kemin; Maltseva, Natalia Ivanovna; Chen, Siquan; Nicolaescu, Vlad; Dvorkin, Steve; Furlong, Kevin; Kathayat, Rahul S.; Firpo, Mason R.; Mastrodomenico, Vincent; Bruce, Emily A.; Schmidt, Madaline M.; Jedrzejczak, Robert; Muñoz-Alía, Miguel Á.; Schuster, Brooke; Nair, Vishnu; Botten, Jason W.; Brooke, Christopher B.; Baker, Susan C.; Mounce, Bryan C.; Heaton, Nicholas S.; Dickinson, Bryan C.; Jaochimiak, Andrzej; Randall, Glenn; Tay, Savaş
title: Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro
date: 2020-09-01
journal: bioRxiv
DOI: 10.1101/2020.08.31.274639
sha: 2bc1855f71d4c480d4522774bf75b5c718d693c6
doc_id: 1054920
cord_uid: x6hc4bhn

There is an urgent need for anti-viral agents that treat SARS-CoV-2 infection. The shortest path to clinical use is repurposing of drugs that have an established safety profile in humans. Here, we first screened a library of 1,900 clinically safe drugs for inhibiting replication of OC43, a human beta-coronavirus that causes the common-cold and is a relative of SARS-CoV-2, and identified 108 effective drugs. We further evaluated the top 26 hits and determined their ability to inhibit SARS-CoV-2, as well as other pathogenic RNA viruses. 20 of the 26 drugs significantly inhibited SARS-CoV-2 replication in human lung cells (A549 epithelial cell line), with EC50 values ranging from 0.1 to 8 micromolar. We investigated the mechanism of action for these and found that masitinib, a drug originally developed as a tyrosine-kinase inhibitor for cancer treatment, strongly inhibited the activity of the SARS-CoV-2 main protease 3CLpro. X-ray crystallography revealed that masitinib directly binds to the active site of 3CLpro, thereby blocking its enzymatic activity. Mastinib also inhibited the related viral protease of picornaviruses and blocked picornaviruses replication. Thus, our results show that masitinib has broad anti-viral activity against two distinct beta-coronaviruses and multiple picornaviruses that cause human disease and is a strong candidate for clinical trials to treat SARS-CoV-2 infection.

On January 2020, SARS-CoV-2 was identified as the causative agent of a new respiratory syndrome that was later named Corona Virus Disease 19 (COVID-19) 1 . The virus has rapidly spread throughout the world, causing an ongoing pandemic, with over 25 million confirmed cases and over 850,000 deaths (as of August 30 th 2020) 2 . SARS-CoV-2 is a member of Coronaviridae, a family of enveloped, single-strand, positive-sense RNA viruses with a relatively large genome 3 . This family includes both human and animal pathogens, including two other emerging human pathogens (SARS-CoV and MERS-CoV) as well four endemic human viruses that are the second most common cause of the common cold (HCoV-OC43, 229E, NL63 and HKU1) 4 .

Upon entry into the host cell cytoplasm, the viral genome is translated into a polyprotein that must be cleaved into the individual viral proteins for infection to proceed. This cleavage is mediated by two virally encoded proteases: the main viral protease, known as Mpro, 3CLpro or non-structural protein 5 (nsp5) and a second protease known as the papain-like protease, PLpro, a domain within nsp3 3 . There is much interest in developing de-novo inhibitors to target these proteases 5-10 but the full clinical development of such drugs is a time-consuming process, usually requiring several years.

While several promising vaccine candidates have entered human clinical trials 11 , their success is not guaranteed. Moreover, even if some are approved, it will be some time until both production and vaccination efforts can reach the levels needed to control this global outbreak. Therefore, there is a need for new treatment options for COVID-19. While the antiviral remdesivir, an RNA-dependent RNApolymerase inhibitor originally developed to treat Hepatitis C virus and later repurposed for Ebola, did receive an emergency use authorization from the FDA due to its ability to shorten COVID-19 hospitalization times 12 , there are currently no FDA-approved specific antivirals for treating SARS-CoV-2 infection and the introduction of additional antivirals would help to reduce morbidity and mortality.

One obvious way to speed up drug discovery is through the use of drug-repurposing screens, looking to identify safe-in-human drugs with potential anti-coronavirus properties 9, 13, 14 . Here, we employed a three-tiered approach for drug repurposing, to identify potential broad-spectrum anticoronavirus drugs that specifically target the viral main protease, 3CLpro. We first screened a library of 1,900 safe-in-human drugs for their ability to inhibit HCoV-OC43 infection. HCoV-OC43 is a biosafety level 2 (BSL2) agent and a relatively safe model organism that enables the study of coronavirus infections outside of high biocontainment facilities. We then validated the anti-viral properties of the top hits against SARS-CoV-2, and finally investigated the drugs' ability to inhibit the enzymatic activity of the main SARS-CoV-2 protease 3CLpro.

We report here on the identification of 20 safe-in-human drugs that are able to inhibit SARS-CoV-2 infection in human lung cells and on the mechanism of action of one of these, masitinib (a tyrosinekinase inhibitor) -which we find to be a bone-fide 3CLpro inhibitor with broad anti coronaviruses and picornaviruses activity.

We began by screening a library of 1,900 clinically used drugs, either approved for human use or with extensive safety data in humans (Phase 2 or 3 clinical trials), for their ability to inhibit OC43 infection of the human lung epithelial cell line A549 (expressing an H2B-mRuby nuclear reporter). One day after plating, cells were infected at an MOI of 0.3, incubated at 33 o C for 1 hour and drugs were added to a final concentration of 10µM. Cells were then incubated at 33 o C for 4 days, fixed and stained for the presence of the viral nucleoprotein (Fig. 1A) . We imaged the cells at day 0 (following drug addition) and day 4 (after staining) to determine the drugs effect on cell growth and OC43 infection.

We repeated the screen twice and identified 108 drugs that significantly reduced OC43 infection without significant cellular toxicity (Fig. 1B, Fig. S1 , Table S1 ). Of our top hits, we selected 29 drugs for further validation. We determined the EC50 values (drug concentration required to reduce infection by 50%) of these drugs against OC43 infection (Fig. 1C, Fig. S2 ). All of the drugs except erythromycin inhibited OC43 infection in a dose-dependent manner, with EC50 values ranging from 0.04-7µM. The most potent drugs in inhibiting OC43 infection were amphotericin B (an anti-fungal drug, EC50=0.04µM), elbasvir (an anti-viral against HCV, EC50=0.17µM), cediranib (an EGFR inhibitor, EC50=0.52µM) and cepharanthine (an anti-inflammatory drug, EC50=0.77µM). Remdesivir inhibited OC43 infection in the same cells with an EC50 value of 0.9µM.

We proceeded to determine the EC50 values for 26 of these drugs against SARS-CoV-2 infection.

In a high biocontainment (BSL3) facility, A549 cells over-expressing the angiotensin-converting enzyme 2 (ACE2) receptor were treated with the drugs for 2 hours, infected with SARS-CoV-2 at an MOI of 0.5, incubated for 2 days, fixed, and stained for the viral spike protein (as a marker of SARS-CoV-2 infection).

After staining, the cells were imaged under a microscope to quantify the fraction of infected cells. Of the 26 drugs tested, 20 (77%) inhibited SARS-CoV-2 infection in a dose dependent manner ( Fig. 2A, Fig. S3 ).

Interestingly, the most potent drugs against OC43 infection (amphotericin B and elbavir) did not inhibit SARS-CoV-2 infection. The pleiotropic drug cepharanthine was the most potent inhibitor of SARS-CoV-2 infection (EC50=0.13µM), followed by flupenthixol (an anti-psychotic, EC50=0.56µM) and desloratidine (an anti-histamine, EC50=0.9µM). In comparison, remdesivir inhibited SARS-CoV-2 infection with an EC50 value of 0.1µM. A comparison of the EC50 values obtained against OC43 and SARS-CoV-2, as well as the chemical structures of the drugs, is shown in Table S2 . Many of the identified drugs are anti-psychotic and anti-allergic drugs that share a similar tricyclic structure, in agreement with the previous identification of olanzapine (a tricyclic anti-depressant) as an anti-SARS-CoV-2 drug 13 .

We further evaluated the effect of several drugs on the production of viable progeny viruses. Cells were treated with 10µM of the drugs for 2 hours, infected at an MOI of 0.5 and the supernatant collected 2 days after for titration (Fig. 2B) . Cepharanthine, azelastine, and masitinib completely eliminated SARS-CoV-2 progeny production (>5-logs decrease), while flupenthixol and desloratidine reduced viral titers by about 2-logs. Ultimately, our screen identified 20 safe-in-human drugs that are able to inhibit both OC43 and SARS-CoV-2 infection in vitro.

We next examined the drugs ability to inhibit the SARS-CoV-2 main protease (also known as 3CLpro, Mpro and nsp5). 3CLpro is an attractive target for anti-viral drugs, as it indispensable for the viral replication cycle and is well conserved among coronaviruses 15 . We first tested the ability of 20 drugs that inhibited both SARS-CoV-2 and OC43 infection to inhibit 3CLpro activity in 293T cells transfected with a FlipGFP reporter system 16 at a single concentration of 10µM. In this assay, 3CLpro cleavage of the FlipGFP reporter is needed to produce GFP fluorescence, and thus the level of GFP+ cells reports on 3CLpro activity. 8 drugs showed a statistically significant decrease in the percentage of GFP-expressing cells -retapamulin, conivaptan, bafetinib, raloxifene, imatinib, lapatinib, vilazodone and masitinib (Fig. 3A, Fig. S4 ). Standing out among these was masitinib, a c-kit/PDGFR inhibitor in multiple phase 3 clinical trials, which completely inhibited 3CLpro activity. Masitinib preferentially binds and inhibits the mutant form of c-kit 17 and has been approved for treatment of mast-cell tumors in dogs 18 . Masitinib was also evaluated in phase 2 and 3 clinical trials in humans for the treatment of cancer 19 , asthma 20 , Alzheimer's 21 , multiple sclerosis 22 and amyotrophic lateral sclerosis 23 .

Therefore, we proceeded to determine the IC50 value (the drug concentration that causes a 50% reduction in enzymatic activity) of masitinib inhibition of 3CLpro activity in two distinct cellular assays; the same FlipGFP reporter assay described above (Fig. 3B) , as well as a luciferase reporter assay adapted for SARS-CoV-2 24 (Fig. 3C ). These assays, performed independently at the University of Chicago and Duke University, determined the IC50 value to be 2.5µM (Fig. 3B,C) , similar to the EC50 values determined against OC43 (2.1µM, Fig. 1C ) and SARS-CoV-2 (3.2µM, Fig. 2A ) infections, suggesting that masitinib inhibition of coronavirus infection is achieved by inhibiting 3CLpro activity.

We additionally evaluated the IC50 value of masitinib using a novel cell-free assay with purified 3CLpro and a methyl-amino coumarin (AMC)-tagged peptide, whose fluorescent signal is uncaged upon 3CLpro proteolytic activity (Fig. 3D , IC50 = 35 µM. See Methods for complete description of the assay).

While this assay determined a higher IC50 value than the cell-based assays, it strongly suggested that direct interaction of masitinib with the viral protease is responsible for its effects on SARS-CoV-2 replication.

To obtain further mechanistic understating of the mode of 3CLpro inhibition by masitinib we determined the high-resolution structure of masitinib-bound 3CLpro using X-ray crystallography (Fig. 4) . The structure indicates that masitinib binds non-covalently into the shallow, elongated grove between domains I and II of 3CLpro and is crossing the 3CLpro active site. The enzyme is a dimer and both active sites are occupied by masitinib. Specifically, masitinib's pyridine ring packs into the S1 substrate pocket of 3CLpro peptide recognition site 25 . In addition to hydrophobic and Van der Waals interactions between the ring and its surrounding pocket-forming residues, it forms a hydrogen bond with His163, located at the bottom of the S1 pocket. Masitinib's aminothiazole ring forms a hydrogen bond with the carbonyl of His164 and interacts directly with the key catalytic residue -Cys145. The second catalytic residue, His41, forms a nearly perfect π-π stacking with masitinib's hydrophobic toluene ring that occupies the S2 binding pocket. These three active groups (pyridine, aminothiazole and toluene rings) contribute the majority of interactions between masitinib and 3CLpro, bind the key active site residues and effectively block the peptide substrate access to the protease catalytic dyad 26 , thus preventing polyprotein cleavage.

Taken together, our results show that masitinib, originally designed as a tyrosine-kinase inhibitor and considered for treatment of a number of human diseases, harbors potent anti-coronavirus activity through its direct binding to and inhibition of the virus main protease.

Since masitinib directly binds and inhibits the coronaviruses 3CL protease, we asked if it is also effective against the 3C protease of picornaviruses (human pathogens that cause a range of diseases including meningitis, hepatitis, and poliomyelitis) given the extensive structural homology and substrate specificity shared between these viral proteases 27 . Using a luciferase reporter assay 28 , we indeed found that masitinib significantly inhibited the activity of the 3C protease in cells (Fig. 5A ). Masitinib was also effective in blocking the replication of multiple picornaviruses ( Fig. 5B ) but not of other RNA viruses (Fig. S5 ). Thus, we conclude that masitinib is a relatively broad-spectrum anti-viral, able to inhibit multiple corona-and picorna-viruses, but not other RNA viruses that do not rely on a 3CL-like protease to complete their life cycle.

In conclusion, we have shown that OC43, a BSL-2 pathogen that can be readily studied in most virological labs, is a good model system to screen potential anti-viral drugs against SARS-CoV-2 infection, since most drugs that inhibited OC43 replication also inhibited SARS-CoV-2 in our measurements. We identified 20 safe-in-human drugs that should be considered for advancement for clinical trials and identified masitinib as a direct anti-viral agent that binds and inhibits 3CLpro.

While masitinib binds to 3CLpro in a non-covalent manner, it shows better efficacy against SARS-CoV-2 replication in vitro than the recently reported covalent, pre-clinical, 3CLpro inhibitor 13b 29 . While masitinib's EC50 value is higher than that of two other, pre-clinical, covalent inhibitors, 11a and 11b 10 , it showed superior inhibition of progeny production at 10µM (over 5-logs for masitinib, compared to 2-logs for 11a and 11b).

It is important to note that in addition to the direct anti-viral effect we have uncovered here, masitinib has been shown to decrease airway inflammation and improve lung functions in a feline model of asthma 30 . Given that a main pathology of SARS-CoV-2 is ARDS (acute respiratory distress syndrome), the combined anti-viral and anti-inflammatory properties of masitinib might prove highly beneficial for treating COVID-19.

Though here we highlighted masitinib, given its direct inhibitory effect on the viral main protease, we emphasize that the other drugs we identified as SARS-CoV-2 inhibitors should also be investigated more. Topical drugs in particular represent an interesting class of drugs for further exploration. These drugs could be considered for use as prophylactics in high risk populations, such as healthcare workers, due to their ease of use, favorable safety profile, and local delivery of high doses to areas of viral replication. In addition to azelastine (a nasally administered antihistamine used to treat rhinitis), which we have shown inhibits both OC43 (Fig. 1C ) and SARS-CoV-2 ( Fig. 2) , several of the identified hits in our primary screen against OC43 are also administered topically to either the nose or lungs (Table S1 ). These include salmeterol, budesonide, beclomethasone, fluticasone, and xylometazoline.

Future efforts should evaluate the efficacy of the identified drugs in preventing or treating COVID19 patients as well as decipher the mechanism by which these drugs are able to inhibit betacoronaviruses replication. While any single agent anti-viral therapy is likely to cause viral adaption and the emergence of resistance mutants, a previous work suggested that CoVs that escape 3CLpro inhibition by mutating the protease show decreased replication and pathogensis 31 

The Authors declare no competing interests

A549 expressing H2B-mRuby were generated by first infecting A549 cells (ATCC CCL-185) with a lentivirus (carrying H2B-mRuby), and FACS-sorting mRuby+ cells. They were maintained as a polyclonal population and grown in DMEM+10% BCS (Bovine Calf Serum). These cells were used for all OC43 infections. Ace2- Armstrong 53b strain was generated as previously described 33, 34 . Working stocks were generated in Vero E6 cells, and the same cells were used to measure virus titers. The Measles Virus used was derived from the molecular cDNA clone of the Moraten/Schwartz vaccine strain 35 . The recombinant Measles virus was engineered to express firefly luciferase as previously described 36 .

A549-mRuby cells were seeded (3,000 cells per well) in nine 384-well plates using Multidrop combi. Cells were seeded in a final volume of 30ul with DMEM+10% BCS. The following day, 20ul of OC43 were added (MOI 0.3) and incubated at 33°C, 5% CO 2 for 1 hour. 50nl from the Selleck FDA-approved drug library (cat #L1300, Selleck) were added (1:1,000 dilution). Two columns (32 wells) were left uninfected and two columns were treated with DMSO and virus (no drug control). Cells were imaged using the IncuCyte S3 to measure cell numbers at day 0. Cells were incubated for 4 days at 33°C, 5% CO2 and were stained for OC43 nucleoprotein. All the following steps were performed at room temperature. Cells were fixed in 50ul 4% PFA/PBS for 15 min, blocked with 50ul 10% BSA+0.5% Triton X-100 in PBS for 30 minutes, stained with 50ul anti-OC43 (cat # MAB9013, Milipore) diluted 1:2,000 in 2% BSA+0.1% Triton X-100 in PBS for 1 hour, washed with 50ul PBS three times, stained with anti-mouse-AlexaFluor488 diluted 1:1,000 in 2% BSA+0.1% Triton X-100 in PBS for 1 hour, washed with 50ul PBS three times and imaged on the IncuCyte S3 (day 4). The screen was performed twice.

The following parameters were extracted from the images: number of cells at day 0, number of cells at ay 4 and total OC43 staining intensity at day 4. For analysis, OC43 staining intensity was normalized to the number of cells in the well and further normalized to the mean of the no drug controls, which was set to 100. We removed from analysis compounds that showed significant effect on cell growth. For each plate, we considered a drug as a putative hit if it reduced OC43 staining by over 3 standard deviations from the mean of the no drug controls. Drugs were considered hits if they were not toxic and reduced OC43 staining by over 3 standard deviations in both repeats. The full list of screened drugs, as well as their effect on cell growth and OC43 staining is summarized in Table S1 .

Dose-response analysis of OC43 infection was done similarly to the drug screening, except cells were seeded at a concentration of 5,000 cells per well and the media contained 2% BCS instead of 10% BCS.

OC43 staining was performed 2 days after infection and analyzed similarly to what was described for the drug screening. A sigmoid fit was used to extract EC50 values using Matlab. In a few cases we were unable to fit a sigmoid curve to the data and EC50 values were estimated from the graphs (these are denoted by ~ in Fig. S2 ).

All SARS-CoV-2 infections were performed in biosafety level 3 conditions at the Howard T. Ricketts Regional Biocontainment Laboratory. Ace2-A549 cells in DMEM +2% FBS were treated with drugs for 2 hours with 2-fold dilutions beginning at 10M in triplicate for each assay. Cells were infected with an MOI of 0.5 in media containing the appropriate concentration of drugs. After 48 hours, the cells were fixed using 3.7% formalin, blocked and probed with mouse anti-Spike antibody (GTX632604, GeneTex) diluted 1:1,000 for 4 hours, rinsed and probed with anti-mouse-HRP for 1 hour, washed, then developed with DAB substrate 10 minutes. Spike positive cells (n>40) were quantified by light microscopy as blinded samples.

For SARS-CoV-2 plaque titers, cell supernatants from the infection described above were serially diluted (10-fold steps were used) and used to infect Vero E6 cells for 1 hour. Inoculum was removed and 1.25% methylcellulose DMEM solution was added to the cells and incubated for 3 days. Plates were fixed in 1:10 formalin for 1 hour, stained with crystal violet for 1 hour and were counted to determine plaque forming units (PFU)/ml. 

The cell-free inhibition assay was done in triplicates at 25°C using 96-well plates. Reactions containing the different concentrations of masitinib (0-1,000 µM) and 3CLpro enzyme (0.4 µM) in Tris-HCl pH 7.3, 1 mM EDTA were incubated for approximately five minutes. Reactions were then initiated with Ac-TVLQ-AMC probe substrate (40 µM), shaken linearly for 5 seconds. Fluorescence emission intensity (excitation λ: 364 nm; emission λ: 440 nm) was measured continuously (Synergy Neo2 Hybrid). Data were fit using a sigmoid curve fit in Matlab.

Cloning of 3CLpro from SARS CoV-2 was based upon the original cloning of SARS-CoV 3CLpro 37 which was connected to a Vac-Man vacuum manifold. Unbound protein was washed out using controlled suction lysis buffer (160 ml). 3CLpro was eluted using 15 ml of buffer containing 500 mM NaCl, 5% (v/v) glycerol, 50 mM HEPES pH 8.0, 500 mM imidazole pH 8.0 and 1mM TCEP. The fractions containing 3CLpro were pooled, and rhinovirus 3C His6 tagged protease was added at a 1:25 protease:protein ratio and incubated at 4 °C overnight to cleave the C-terminal His6 tag, resulting in a 3CLpro with an authentic N and C-termini. 10 kDa MWCO filter (Amicon-Millipore) was used to concentrate the protein solution, which was subsequently applied to Superdex 75 column, pre-equilibrated with lysis buffer. The fractions containing 3CLpro were pooled together and run through 2 ml of Ni resin. We collected the flow through and replaced the lysis buffer with crystallization buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT (1,4-Dithiothreitol, Roche, Basel, Switzerland)) using a 10 kDa MWCO filter. 3CLpro solution was concentrated to 49 mg/ml, was aliquoted, frozen and stored at -80 o C.

Crystallization were carried out using previous protocols 38 

Cryo-cooled crystals (100 K) were measured using single-wavelength X-ray diffraction experiments at the 19-ID beamline of the Structural Biology Center, Advanced Photon Source at Argonne National Laboratory (we used the SBCcollect program). We integrated, scaled and merged intensities of each data set (HKL-3000 program suite was used 39 ). The structure of 3CLpro in complex with masitinib was determined using the molecular replacement method 40 with an apo form of 3CLpro (PDB code: 7JFQ) as a search template.

In the difference Fourier maps, extra electron densities were observed in the substrate binding site of 3CLpro and were subsequently identified as the contribution of masitinib. One data set with a resolution limit up to 1.60 Å was selected for further model rebuilding, including building masitinib into extra densities using the program Coot 41 and refinement using the program phenix.refine 42 (Table 1) . We used MOLPROBITY 43 to validate the stereochemistry of the structure (Table 1) . 

We performed low resolution mass spectral and liquid chromatography analyses using the Advion Expression-L mass spectrometer (Ithaca, NY), which was coupled to an Agilent 1220 Infinity LC System. 

Prior to infection, Huh7 cells were pretreated for two hours. Virus was diluted using serum-free DMEM 

Huh7 cells were transfected with LipoD293 (SignaGen Laboratories) with 3C substrate, 3C protease (derived from CVV3) and a Renilla transfection control plasmid (siCheck). Protease and target constructs were generated using protocols previously described 28 

One day prior to infection, A549 cells were seeded in 12 well dishes (80,000 cells per well). Cells were infected with rLCMV at an MOI of 0.01 for one hour at 37°C. The inoculum was removed and cells were overlaid with 1 ml of complete media containing masitinib or DMSO only control. Supernatants were harvested at 48 hours after infection, were clarified and titrated by a previously described immunofocus assay 44, 45 , using a mouse anti-LCMV nucleoprotein antibody (1-1.3, kindly provided by M.

Buchmeier) and a peroxidase-labeled goat anti-mouse antibody (SeraCare).

Vero cells were infected with a luciferase-expressing Measles virus at an MOI of 0.01 for 90 minutes. We removed the inoculum and added fresh medium containing masitinib or DMSO to the cells for further culture. Three days later, firefly luciferase activity was measured by adding 0.5mM of D-Luciferin to each well and was quantified with an Infinite M200 Pro multimode microplate reader.

For all experiment described, the size of the sample (n) refers to independent biological samples tested.

All analyses were performed in Matlab. Multiple-comparison corrections was performed using the FDR method.

All data are available from the corresponding author upon reasonable request. The X-ray structure of 3CLpro-bound masitinib has been deposited to PDF under accession number 7JU7. the %OC43 staining of mock-infected cells (green), no-drug controls (black), drugs with no effect on OC43 infection (blue), and screen hits (red). Overall agreement between the two repeats is high (R 2 =0.81) C.

Dose response curves of remdesivir and the top hits from the screen, n = 3. Individual measurements are shown as semi-transparent circles (note that some circles overlap). performed to screen for potential inhibition of 3CLpro by the identified drugs at a single concentration (10µM). Shown are the drugs that showed a statistically significant reduction in 3CLpro activity (p-value<0.05, one-tailed t-test, FDR-corrected). n=6. The data for the remaining tested drugs is shown in Figure S4 . Individual measurements are shown in circles. Bars depict mean ± s.e. Masitinib treatment completely inhibited 3CLpro activity. B. Dose-response curve for 3CLpro inhibition by masitinib using the FlipGFP reporter assay, n = 6. Individual measurement shown as circles. C. Dose-response curve for 3CLpro inhibition by masitinib using a luciferase reporter assay, n = 3. Induvial measurement shown as circles D.

Dose-response curve for 3CLpro inhibition in a cell-free assay using purified 3CLpro and a flurogenic peptidic substrate, n = 3. Individual measurement shown as circles. Figure S4 . Effect of remaining tested drugs on 3CLpro FlipGFP reporter assay. A FlipGFP reporter assay was performed to screen for potential inhibition of 3CLpro by the identified drugs at a single concentration (10µM). Shown are all the drugs that did not show a significant reduction in 3CLpro activity (p-value>0.05, one-tailed t-test, FDR-corrected). n = 6. Individual measurements are shown in circles. Bars depict mean ± s.e. The drugs that showed statistically significant inhibition of 3CLpro are shown in Figure 3A . 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Coronavirus Update (Live): 22,559,115 Cases and 790,019 Deaths from COVID-19 Virus Pandemic -Worldometer

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Viruses and Bacteria in the Etiology of the Common Cold

The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020

SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening. bioRxiv

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

The journey of remdesivir: from Ebola to COVID-19

Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs

Development of a fluorescence based, highthroughput SARS-CoV-2 3CLpro reporter assay

(AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

Masitinib is safe and effective for the treatment of canine mast cell tumors

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials -PubMed

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics

Masitinib for the treatment of mild to moderate Alzheimer's disease

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds

Coxsackievirus B3 Responds to Polyamine Depletion via Enhancement of 2A and 3C Protease Activity

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma

Coronaviruses Resistant to a 3C-Like Protease Inhibitor Are Attenuated for Replication and Pathogenesis, Revealing a Low Genetic Barrier but High Fitness Cost of Resistance

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA

The Lymphocytic Choriomeningitis Virus Matrix Protein PPXY Late Domain Drives the Production of Defective Interfering Particles

A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge

Probing Morbillivirus Antisera Neutralization Using Functional Chimerism between Measles Virus and Canine Distemper Virus Envelope Glycoproteins

Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction

High-throughput protein purification and quality assessment for crystallization

HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes

Molecular replacement with MOLREP

Coot: model-building tools for molecular graphics

Improved crystallographic models through iterated local density-guided model deformation and reciprocal-space refinement

MolProbity: all-atom structure validation for macromolecular crystallography

Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV

A novel phosphoserine motif in the LCMV matrix protein Z regulates the release of infectious virus and defective interfering particles